Weekly Analysts’ Ratings Updates for Aclaris Therapeutics (ACRS)

Aclaris Therapeutics (NASDAQ: ACRS) recently received a number of ratings updates from brokerages and research firms:

• 11/20/2024 – Aclaris Therapeutics was upgraded by analysts at Cantor Fitzgerald from a “neutral” rating to an “overweight” rating.
• 11/19/2024 – Aclaris Therapeutics was upgraded by analysts at Leerink Partnrs from a “hold” rating to a “strong-buy” rating.
• 11/19/2024 – Aclaris Therapeutics was upgraded by analysts at Leerink Partners from a “market perform” rating to an “outperform” rating. They now have a $7.00 price target on the stock, up previously from $2.00.
• 11/19/2024 – Aclaris Therapeutics was upgraded by analysts at Jefferies Financial Group Inc. from a “hold” rating to a “buy” rating. They now have a $7.00 price target on the stock, up previously from $2.00.
• 11/19/2024 – Aclaris Therapeutics was upgraded by analysts at BTIG Research from a “neutral” rating to a “buy” rating. They now have a $8.00 price target on the stock.
• 11/18/2024 – Aclaris Therapeutics was upgraded by analysts at Piper Sandler from a “neutral” rating to an “overweight” rating. They now have a $13.00 price target on the stock, up previously from $3.00.
• 11/15/2024 – Aclaris Therapeutics was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating.
• 11/7/2024 – Aclaris Therapeutics was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating.

Aclaris Therapeutics Price Performance

Shares of ACRS stock traded up $0.13 on Friday, hitting $3.94. 771,147 shares of the stock traded hands, compared to its average volume of 1,403,778. Aclaris Therapeutics, Inc. has a 52 week low of $0.80 and a 52 week high of $5.17. The firm has a 50 day simple moving average of $2.31 and a two-hundred day simple moving average of $1.58. The firm has a market cap of $281.43 million, a price-to-earnings ratio of -7.58 and a beta of 0.45.

Aclaris Therapeutics (NASDAQ:ACRS) last posted its quarterly earnings results on Wednesday, November 6th. The biotechnology company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.03). Aclaris Therapeutics had a negative return on equity of 40.26% and a negative net margin of 136.65%. The business had revenue of $4.35 million during the quarter, compared to analysts’ expectations of $8.31 million. Sell-side analysts forecast that Aclaris Therapeutics, Inc. will post -0.75 EPS for the current year.

Insider Transactions at Aclaris Therapeutics

In related news, Director Anand Mehra acquired 666,666 shares of the firm’s stock in a transaction on Tuesday, November 19th. The shares were acquired at an average cost of $2.25 per share, for a total transaction of $1,499,998.50. Following the completion of the transaction, the director now directly owns 710,030 shares in the company, valued at approximately $1,597,567.50. This trade represents a 1,537.37 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 6.40% of the company’s stock.

Institutional Trading of Aclaris Therapeutics

Several institutional investors have recently added to or reduced their stakes in the company. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Aclaris Therapeutics in the 2nd quarter valued at about $119,000. Assenagon Asset Management S.A. purchased a new stake in shares of Aclaris Therapeutics in the third quarter valued at approximately $214,000. Connor Clark & Lunn Investment Management Ltd. increased its holdings in Aclaris Therapeutics by 187.6% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 332,406 shares of the biotechnology company’s stock worth $382,000 after purchasing an additional 216,826 shares during the period. Geode Capital Management LLC raised its position in Aclaris Therapeutics by 9.3% during the 3rd quarter. Geode Capital Management LLC now owns 846,446 shares of the biotechnology company’s stock valued at $974,000 after purchasing an additional 72,309 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. purchased a new stake in shares of Aclaris Therapeutics in the 3rd quarter worth $1,053,000. Institutional investors own 98.34% of the company’s stock.

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.